Guardant Health’s Q4 Gross Margin Rises to 66%, Projects $220M Cash Burn in 2026
Guardant Health's Q4 non-GAAP gross margin rose to 66% from 63% on cost efficiencies, while management projects 20% growth in Guardant360 testing volumes and strong Reveal uptake. The company expects $220 million annual cash burn in 2026 and awaits FDA decision on Guardant360 Liquid CDx.
1. Q4 Financial Performance
Guardant Health reported non-GAAP gross margin of 66% in Q4 2025, up from 63% year-over-year, driven by cost reductions and operational efficiencies. Concurrent ordering reimbursement challenges for tissue and blood tests remain, potentially limiting growth in the tissue business.
2. Product Volume and Growth Guidance
Management projects at least 20% growth in Guardant360 testing volumes and continued robust uptake of the Reveal therapy monitoring product throughout 2026. Upgrades to the Smart platform are expected to accelerate Guardant360 Tissue volume growth.
3. Cash Burn and Investment
The screening business will drive high investment levels, with an anticipated $220 million cash burn in 2026 similar to the prior year. Expansion of the commercial infrastructure for Shield includes ongoing sales and marketing buildout.
4. FDA Approval and Pipeline
The company awaits FDA decision on Guardant360 Liquid CDx approval, which could influence future revenues, and expects to finalize ADLT pricing in the second half of 2026 without impacting that year's pricing. Reveal Ultra is slated for launch this year, offering enhanced clinical sensitivity in the tumor-informed testing space.